Search

Descubra cómo MSK utiliza el enfoque de observación y espera para el cáncer de recto, que permite preservar la calidad de vida de los pacientes al tratar con éxito el cáncer de recto sin necesidad de extirpar el recto.

… Friday, February 28, 2025 Existe una alternativa para tratar a algunos pacientes con cáncer de recto que permite evitar la extirpación quirúrgica del recto y los efectos secundarios relacionados, que pueden incluir cambios en la función sexual y la fertilidad y la posibilidad de tener que usar una bolsa

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning they did not need to undergo surgery, radiation, or chemotherapy.

… Sunday, April 27, 2025 An approach pioneered at Memorial Sloan Kettering Cancer Center (MSK) that caused rectal cancer tumors with a specific genetic mutation to disappear in 100% of clinical trial participants has been expanded to treat other types of cancer, including stomach (gastric) , colon , esophageal

Obtenga información sobre un ensayo clínico en el que se utilizó únicamente inmunoterapia para tratar a personas con varios tipos diferentes de cáncer, lo que significa que no tuvieron que someterse a cirugía, radioterapia ni quimioterapia.

… Sunday, April 27, 2025 Un enfoque en el que Memorial Sloan Kettering Cancer Center (MSK) fue pionero y que hizo que los tumores de cáncer de recto con una mutación genética específica desaparecieran en el 100 % de los participantes en el ensayo clínico se ha ampliado para tratar otros tipos de cáncer

Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD, has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells, from self-destructing. During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness. The use of “genetic cloaking” prevents immune cell apoptosis, enhancing the effectiveness of cellular immunotherapies for liquid and solid cancers in mouse models. This new technique is also effective in protecting human cancer-fighting immune cells. These findings lay the groundwork for a potentially universal gene-engineering strategy to safely increase the potency of cellular immunotherapies for a broad range of cancers.

… Tuesday, January 29, 2019 Bottom Line: Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD , has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells

The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.

… Sunday, September 20, 2020 Summary In a study of people with lung cancer whose tumors contained the mutation targeted by sotorasib, 52 of 59 patients experienced disease control, which means that their tumors stopped growing. Update: On January 30, 2021, Memorial Sloan Kettering lung cancer expert Bob

An MSK program helps lung cancer survivors stay healthy following successful treatment for their disease.

… Tuesday, December 10, 2024 Summary With more people surviving longer after lung cancer , close management of those who have had successful treatment is more important than ever. MSK’s Lung Cancer Survivorship Program provides regular screening for recurrent cancers or new tumors, as well as guidance

Un programa de MSK ayuda a los sobrevivientes de cáncer pulmonar a mantenerse saludables después de un tratamiento exitoso contra su enfermedad.

… Tuesday, December 10, 2024 Resumen Debido a que más personas sobreviven por más tiempo después de un cáncer pulmonar , el seguimiento cercano de quienes han recibido un tratamiento exitoso es más importante que nunca. El Programa de Sobrevivencia de Cáncer Pulmonar de MSK ofrece exámenes regulares para

Learn how a blood test could someday provide a way to detect cancers at an early stage.

… Friday, October 13, 2023 A blood test that could detect multiple cancers at their earliest stages has long been a dream of the medical community. Now results from a pilot study, published in The Lancet , suggest that a single blood test might identify the presence of more than 50 cancer types . The experimental

In her new role as Chief Health Equity Officer, Carol Brown, MD, took part in The Atlantic’s virtual event, People v. Cancer: Equity in Care.

… Monday, November 2, 2020 In her new role as Chief Health Equity Officer, Carol Brown, MD , took part in The Atlantic’s virtual event, People v. Cancer: Equity in Care . The online session explored the health equity challenges facing patients, providers, and institutions and what is being done to improve

The majority of young women at an increased risk of breast cancer due to chest radiation treatment for childhood cancer are not following breast cancer screening recommendations, according to a recently released, detailed assessment appearing in the January 28, 2009, issue of the Journal of the American Medical Association.

… Tuesday, January 27, 2009 The majority of young women at an increased risk of breast cancer due to chest radiation treatment for childhood cancer are not following breast cancer screening recommendations, according to a recently released, detailed assessment appearing in the January 28, 2009, issue of